Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

7b837bdd-5a59-47f6-a1aa-259142234bd5

3c7bc4f6-652c-5260-91c4-89ba1ce296e0

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
age_years
80

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • IL6_JAK_STAT3_SIGNALING+0.230
  • HEDGEHOG_SIGNALING+0.210
  • ALLOGRAFT_REJECTION+0.200
  • INFLAMMATORY_RESPONSE+0.200
  • INTERFERON_ALPHA_RESPONSE+0.180
  • INTERFERON_GAMMA_RESPONSE+0.170
  • WNT_BETA_CATENIN_SIGNALING+0.110
  • KRAS_SIGNALING_UP+0.090
  • PANCREAS_BETA_CELLS+0.070
  • KRAS_SIGNALING_DN+0.030

Top 10 suppressed

  • CHOLESTEROL_HOMEOSTASIS-0.520
  • OXIDATIVE_PHOSPHORYLATION-0.430
  • MTORC1_SIGNALING-0.420
  • GLYCOLYSIS-0.400
  • MYC_TARGETS_V2-0.400
  • PROTEIN_SECRETION-0.380
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
  • MYC_TARGETS_V1-0.340
  • ADIPOGENESIS-0.330
  • APICAL_SURFACE-0.320

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG882
mng-umap@100
0.864
2TCGA-93-A4JO-01A-21R-A24X-07
lung-landscapes@6
cohortA10.860
3SRR12202433
bladder-landscape@3
0.858
4TCGA-91-A4BC-01A-11R-A24H-07
lung-landscapes@6
cohortA30.855
5X65f5effa.07f7.4ed3.9e0a.3a0d9d451474
lung-landscapes@6
cohortA10.854
6MNG1098
mng-umap@100
0.846
7ERR2208971
melanoma-umap@29
0.844
8s0122234
melanoma-umap@29
0.844
96b907244-c173-4e29-a163-24258a430477
melanoma-umap@29
0.844
10MNG450
mng-umap@100
0.840

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
IL6_JAK_STAT3_SIGNALING0.230Inavolisib— uncovered
HEDGEHOG_SIGNALING0.210Inavolisib— uncovered
ALLOGRAFT_REJECTION0.200Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.200Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.180Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.170Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.110Inavolisib— uncovered
KRAS_SIGNALING_UP0.090Inavolisib— uncovered
PANCREAS_BETA_CELLS0.070Cobimetinib— uncovered
KRAS_SIGNALING_DN0.030Remibrutinib— uncovered